{
  "ticker": "OCC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965075",
  "id": "02965075",
  "pages": 20,
  "price_sensitive": false,
  "date": "20250702",
  "time": "1246",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06lcxqfj59vdjr.pdf",
  "summary": "### **US Commercialisation Update Summary (Material Information Only)**  \n\n- **First US surgical use of Remplir achieved** \u2013 Initial low volumes to build familiarity.  \n- **14 nerve repair specialist distributors appointed** \u2013 Covering 25 states, initial focus on east coast.  \n- **Logistics established** \u2013 2,000 units shipped to US (1,000 warehoused). Uniphar\u2019s GMP facility operational.  \n- **Sales ramp-up expected in 1H FY26** \u2013 Key milestones (FDA clearance, distributor onboarding, hospital approvals) on track.  \n- **Manufacturing capacity secured** \u2013 100,000-unit annual capacity, no near-term expansion needed.  \n- **Clinical data supports adoption** \u2013 85% functional recovery rate in trials; interim suturing study shows superiority vs. standard repair.  \n- **Upcoming catalysts (CY25)** \u2013 Additional US sales hires (Q3), new market distributor appointments (Canada, Hong Kong, Thailand), EU/UK/Brazil submissions (Q4).  \n- **Market opportunity** \u2013 Targeting US$1.6B nerve repair TAM; current devices used in only ~10% of procedures.  \n\nNo capital raising, financials, or trading-sensitive dates disclosed. Focus remains on commercial execution.  \n\n**Brevity note**: Omitted non-material details (e.g., medical education initiatives, humanitarian efforts). If cash balance or funding needs were critical, they\u2019d be highlighted.",
  "usage": {
    "prompt_tokens": 3689,
    "completion_tokens": 302,
    "total_tokens": 3991,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-02T03:12:30.262031"
}